

Table 19.30  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>

SEER<sup>b</sup> 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Males, 2004-2010

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	
Lymphoid Neoplasm	93,448	67.7 ( 67.3 , 68.1 )	88.3 ( 87.3 , 89.2 )	73.8 ( 73.3 , 74.3 )	57.1 ( 56.3 , 57.9 )			
1 Hodgkin Lymphoma	8,123	84.4 ( 83.4 , 85.3 )	96.8 ( 95.3 , 97.8 )	87.7 ( 86.6 , 88.6 )	52.6 ( 48.2 , 56.8 )			
2 Non-Hodgkin lymphoma	82,956	66.5 ( 66.1 , 67.0 )	86.3 ( 85.1 , 87.4 )	72.1 ( 71.6 , 72.7 )	57.8 ( 57.0 , 58.5 )			
2(a) Non-Hodgkin lymphoma, B-cell	75,497	67.0 ( 66.6 , 67.5 )	87.6 ( 86.2 , 88.9 )	73.2 ( 72.6 , 73.8 )	58.4 ( 57.6 , 59.2 )			
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	3,960	67.9 ( 66.2 , 69.6 )	87.2 ( 85.6 , 88.7 )	35.3 ( 32.2 , 38.5 )	17.1 ( 11.4 , 23.6 )			
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	68,370	67.0 ( 66.5 , 67.5 )	89.5 ( 86.8 , 91.7 )	74.5 ( 73.9 , 75.1 )	58.6 ( 57.7 , 59.4 )			
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	17,804	75.0 ( 73.9 , 76.0 )	- ( - , - )	83.5 ( 82.3 , 84.7 )	68.3 ( 66.7 , 69.8 )			
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	15,341	78.2 ( 77.1 , 79.3 )	- ( - , - )	86.5 ( 85.3 , 87.7 )	71.8 ( 70.1 , 73.5 )			
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	69	51.0 ( 34.3 , 65.4 )	- ( - , - )	- ( - , - )	48.4 ( 29.1 , 65.2 )			
2(a) 2.1.3. Mantle-cell lymphoma	2,394	54.9 ( 52.1 , 57.7 )	- ( - , - )	66.7 ( 63.0 , 70.2 )	44.0 ( 39.9 , 48.0 )			
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	1,547	79.4 ( 75.8 , 82.6 )	- ( - , - )	84.3 ( 79.9 , 87.9 )	76.3 ( 71.0 , 80.7 )			
2(a) 2.2.1. Lymphoplasmacytic lymphoma	660	75.8 ( 69.9 , 80.7 )	- ( - , - )	79.8 ( 72.3 , 85.6 )	73.0 ( 64.3 , 79.9 )			
2(a) 2.2.2. Waldenstrom macroglobulinemia	887	81.9 ( 77.4 , 85.6 )	- ( - , - )	87.5 ( 81.6 , 91.7 )	77.7 ( 71.2 , 82.9 )			
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	17,715	60.4 ( 59.4 , 61.3 )	89.0 ( 84.1 , 92.5 )	67.3 ( 66.2 , 68.4 )	50.8 ( 49.2 , 52.5 )			
2(a) 2.3.1. DLBCL, NOS <sup>c</sup>	17,539	60.4 ( 59.4 , 61.3 )	89.3 ( 84.3 , 92.8 )	67.3 ( 66.2 , 68.4 )	51.0 ( 49.3 , 52.6 )			
2(a) 2.3.2. Intravascular large B-cell lymphoma	-	- ( - , - )	- ( - , - )	- ( - , - )	- ( - , - )			
2(a) 2.3.3. Primary effusion lymphoma	49	22.0 ( 9.6 , 37.7 )	- ( - , - )	22.9 ( 9.7 , 39.4 )	- ( - , - )			
2(a) 2.3.4. Mediastinal large B-cell lymphoma	109	78.2 ( 66.1 , 86.5 )	- ( - , - )	86.5 ( 74.9 , 93.0 )	- ( - , - )			
2(a) 2.4. Burkitt lymphoma/leukemia	1,611	58.9 ( 56.2 , 61.5 )	88.8 ( 85.0 , 91.7 )	54.9 ( 51.5 , 58.2 )	25.2 ( 17.3 , 34.0 )			
2(a) 2.5. Marginal-zone lymphoma (MZL)	4,068	89.4 ( 87.4 , 91.1 )	100.0 ( - , - )	91.1 ( 89.1 , 92.8 )	87.1 ( 83.5 , 89.9 )			
2(a) 2.5.1. Splenic MZL	353	86.6 ( 79.1 , 91.6 )	- ( - , - )	84.6 ( 75.8 , 90.4 )	88.2 ( 73.9 , 94.9 )			
2(a) 2.5.2. Extranodal MZL, MALT <sup>c</sup> type	2,389	93.1 ( 90.4 , 95.0 )	- ( - , - )	94.4 ( 91.9 , 96.1 )	91.3 ( 85.6 , 94.9 )			
2(a) 2.5.3. Nodal MZL	1,326	82.8 ( 79.1 , 85.8 )	- ( - , - )	86.0 ( 81.7 , 89.4 )	79.2 ( 73.2 , 84.0 )			
2(a) 2.6. Follicular lymphoma	8,950	85.5 ( 84.3 , 86.6 )	92.5 ( 71.8 , 98.2 )	89.2 ( 88.0 , 90.3 )	79.4 ( 76.9 , 81.8 )			
2(a) 2.7. Hairy-cell leukemia	1,176	94.2 ( 91.0 , 96.2 )	- ( - , - )	97.7 ( 95.5 , 98.8 )	83.6 ( 74.1 , 89.9 )			
2(a) 2.8. Plasma cell neoplasms	15,480	45.8 ( 44.7 , 46.9 )	- ( - , - )	57.1 ( 55.6 , 58.6 )	35.9 ( 34.3 , 37.4 )			
2(a) 2.8.1. Plasmacytoma	1,092	68.4 ( 64.5 , 72.0 )	- ( - , - )	78.5 ( 74.1 , 82.3 )	52.3 ( 45.3 , 58.7 )			
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	14,388	44.0 ( 42.9 , 45.2 )	- ( - , - )	54.9 ( 53.3 , 56.5 )	34.9 ( 33.3 , 36.4 )			
2(a) 2.9. Heavy chain disease	-	- ( - , - )	- ( - , - )	- ( - , - )	- ( - , - )			
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS <sup>c</sup>	3,167	66.8 ( 64.2 , 69.1 )	76.3 ( 49.8 , 90.1 )	73.1 ( 70.0 , 75.9 )	61.5 ( 57.6 , 65.2 )			

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Table 19.30 - continued  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>

SEER<sup>b</sup> 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Males, 2004-2010

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )		
2(b) Non-Hodgkin lymphoma, T-cell	6,159	62.1 ( 60.6 , 63.6 )	82.7 ( 79.8 , 85.2 )	63.5 ( 61.6 , 65.4 )	48.8 ( 45.4 , 52.1 )			
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	615	62.6 ( 58.3 , 66.7 )	83.0 ( 78.1 , 86.9 )	43.5 ( 36.8 , 50.0 )	- ( - , - )			
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	5,500	62.2 ( 60.5 , 63.8 )	82.5 ( 78.8 , 85.7 )	65.3 ( 63.3 , 67.2 )	49.8 ( 46.3 , 53.2 )			
2(b) 2.1. Mycosis fungoides/Sezary syndrome	1,302	88.5 ( 85.2 , 91.2 )	100.0 ( - , - )	92.6 ( 89.6 , 94.7 )	78.2 ( 69.3 , 84.8 )			
2(b) 2.1.1. Mycosis fungoides	1,263	89.6 ( 86.2 , 92.2 )	100.0 ( - , - )	93.4 ( 90.4 , 95.4 )	79.6 ( 70.3 , 86.3 )			
2(b) 2.1.2. Sezary syndrome	39	50.7 ( 30.3 , 68.0 )	- ( - , - )	- ( - , - )	- ( - , - )			
2(b) 2.2. Peripheral T-cell lymphoma	3,194	54.4 ( 52.2 , 56.5 )	78.5 ( 71.2 , 84.2 )	59.1 ( 56.4 , 61.7 )	42.7 ( 38.8 , 46.6 )			
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS <sup>c</sup>	1,093	36.2 ( 32.6 , 39.8 )	56.4 ( 35.9 , 72.6 )	39.5 ( 34.8 , 44.0 )	29.9 ( 23.9 , 36.1 )			
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	361	37.9 ( 31.6 , 44.3 )	- ( - , - )	48.8 ( 39.7 , 57.3 )	27.0 ( 18.8 , 36.0 )			
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	28	61.2 ( 18.3 , 86.7 )	- ( - , - )	- ( - , - )	- ( - , - )			
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	748	56.1 ( 52.0 , 59.9 )	84.5 ( 75.8 , 90.2 )	57.3 ( 52.3 , 62.0 )	31.8 ( 23.2 , 40.7 )			
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	29	24.2 ( 10.1 , 41.6 )	- ( - , - )	- ( - , - )	- ( - , - )			
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	37	0.0 ( - , - )	- ( - , - )	- ( - , - )	- ( - , - )			
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS <sup>c</sup>	618	80.4 ( 75.3 , 84.6 )	- ( - , - )	84.6 ( 78.7 , 88.9 )	72.6 ( 61.8 , 80.8 )			
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	280	89.8 ( 82.9 , 94.0 )	- ( - , - )	94.0 ( 87.7 , 97.1 )	80.6 ( 64.0 , 90.2 )			
2(b) 2.3. Adult T-cell leukemia/lymphoma	597	61.5 ( 56.8 , 65.8 )	83.9 ( 79.0 , 87.7 )	38.8 ( 31.0 , 46.4 )	9.6 ( 1.7 , 26.2 )			
2(b) 2.4. NK <sup>c</sup> /T-cell lymphoma, nasal-type/aggressive NK <sup>c</sup> -cell leukemia	269	41.5 ( 34.5 , 48.3 )	- ( - , - )	39.2 ( 31.3 , 46.9 )	39.0 ( 24.6 , 53.2 )			
2(b) 2.5. T-cell large granular lymphocytic leukemia	65	52.2 ( 35.1 , 66.8 )	- ( - , - )	72.5 ( 47.3 , 87.1 )	38.1 ( 18.3 , 57.8 )			
2(b) 2.6. Prolymphocytic leukemia, T-cell	73	21.6 ( 11.4 , 34.0 )	- ( - , - )	31.3 ( 16.1 , 47.8 )	10.0 ( 1.8 , 26.8 )			
2(b) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , T-cell	44	44.9 ( 27.5 , 60.9 )	- ( - , - )	- ( - , - )	- ( - , - )			
2(c) Non-Hodgkin lymphoma, unknown lineage	1,300	58.3 ( 55.1 , 61.3 )	83.4 ( 79.0 , 87.0 )	53.1 ( 48.2 , 57.8 )	40.5 ( 34.3 , 46.7 )			
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	596	63.7 ( 59.5 , 67.7 )	83.8 ( 79.4 , 87.4 )	33.7 ( 25.8 , 41.7 )	23.4 ( 13.0 , 35.6 )			
2(c) 2. Prolymphocytic leukemia, unknown lineage	32	38.2 ( 20.4 , 56.0 )	- ( - , - )	- ( - , - )	- ( - , - )			
2(c) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , unknown lineage	672	53.9 ( 49.1 , 58.5 )	- ( - , - )	62.6 ( 56.5 , 68.1 )	44.4 ( 37.0 , 51.5 )			
2(*) 1. Total precursor lymphoma/leukemia <sup>d</sup>	5,171	66.9 ( 65.4 , 68.3 )	86.4 ( 85.0 , 87.7 )	36.7 ( 34.0 , 39.4 )	17.5 ( 12.7 , 22.9 )			
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	45	69.6 ( 49.6 , 82.9 )	- ( - , - )	65.6 ( 44.7 , 80.2 )	- ( - , - )			
4 Lymphoid neoplasm, NOS <sup>c</sup>	2,324	49.4 ( 46.7 , 52.0 )	82.9 ( 65.8 , 91.9 )	59.0 ( 55.4 , 62.3 )	39.7 ( 35.8 , 43.5 )			

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

<sup>d</sup> Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

- Statistic not displayed due to less than 25 cases.